Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102

Funding Supports Aclipse Therapeutics’ and Sheffield Institute of Translational Neuroscience’s Development of M102 in Amyotrophic Lateral Sclerosis 

Radnor, PA — January 26, 2021 – Aclipse Therapeutics (“Aclipse” or “the Company”), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of £1.6 million (approximately US $2.2 million) from the UK’s Medical Research Council (MRC), one of the largest funders of medical research worldwide, to support the translational development of M102. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also referred to as motor neuron disease (MND) or Lou Gehrig’s disease. 

Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND

Aclipse Therapeutics was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent funder of ALS research in Australia. The grant will support the translational development of M102, a drug candidate for the treatment of ALS. M102 showed promise to stop and reverse ALS disease progression, as evidenced by data in preclinical models. Currently, there is no cure for ALS and no effective treatments to halt or reverse the progression of this devastating disease.